性激素受体信号网络驱动胰腺固体伪皮质瘤的发病和治疗
1Department of Hepatobiliary Pancreatic Surgery, Changhai Hospital, 168 Changhai Road, Yangpu District, Shanghai, 200433, China.
Discover oncology
|November 22, 2025
概括
胰腺的固体伪皮质瘤 (SPN) 是一种罕见的瘤,受性激素的影响. 向这些激素和关键途径可能会改善无法切除的SPN的治疗.
科学领域:
- 在瘤学瘤学.
- 内分泌学 在内分泌学.
- 分子生物学分子生物学
背景情况:
- 固体伪皮质瘤 (SPN) 是一种罕见的胰腺瘤,具有低恶性潜力,主要影响年轻女性.
- 妇女的患病率表明性激素在SPN发育中的作用.
- 孕激素受体 (PR),雌激素受体β (ERβ) 和雄激素受体 (AR) 在SPN细胞中的表达表明潜在的荷尔蒙影响.
研究的目的:
- 探索性激素受体和信号通路在SPN病变发生中的作用.
- 根据分子机制,确定SPN的潜在治疗点.
- 调查内分泌和向性结合疗法对SPN的潜力.
主要方法:
- 审查SPN分子生物学和荷尔蒙影响现有研究.
- 对涉及SPN的信号通路的分析,包括Wnt,Notch和Hedgehog.
- 研究表皮-介质细胞过渡 (EMT) 在SPN进展中的作用.
主要成果:
- CTNNB1突变是关键的驱动因素,通过抑制β-catenin降解来激活Wnt途径.
- 性激素受体 (PR,ERβ,AR) 被表达,并可能导致瘤生长.
- 切口,刺信号和EMT也与SPN进展有关.
结论:
- 了解性激素受体和信号通路之间的相互作用对于SPN治疗至关重要.
- 用内分泌和向疗法准这些途径为改善结果提供了希望.
- 组合疗法可能是不可切除或恶性SPN的突破.
相关概念视频
Interactions Between Signaling Pathways
7.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.2K
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
Insulin: The Receptor and Signaling Pathways
2.7K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
2.7K
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
2.6K
Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
2.6K
PI3K/mTOR/AKT Signaling Pathway
5.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.3K
Transducer Mechanism: Enzyme-Linked Receptors
3.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
3.8K


